Loading…
Loading…
NUVA (NuVasive, Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
Globus Medical faced market backlash post-merger with NuVasive, but Q1 FY 2024 showed strong growth and integration efforts. Management revised net sales guidance for FY 2024, aiming for high growth and increased profits with lower operating costs. Valuation scenarios suggest potential for risk capital unlock, and a buy rating is supported on fundamentals and cash flow estimates.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
SAN DIEGO , Aug. 30, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced it will continue its partnership with the Scoliosis Research Society (SRS) as a double diamond sponsor and will attend the 58th Annual Meeting held September 6-9, 2023, in Seattle. "We partner with esteemed societies like SRS because of our shared dedication to clinical research, education, and thought leadership around advancing patient care, especially in the challenging deformity segment," said Chris Barry, chief executive officer at NuVasive.
NEW YORK , Aug. 28, 2023 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Friday, September 1: Goosehead Insurance Inc. (NASD: GSHD) will replace NuVasive Inc. (NASD: NUVA) in the S&P SmallCap 600. S&P MidCap 400 constituent Globus Medical Inc. (NYSE: GMED) is acquiring NuVasive in a deal expected to close soon pending final conditions.
NuVasive's (NUVA) second-quarter 2023 results reflect the robust performance of the U.S. Cervical business.
NuVasive, Inc. (NASDAQ:NUVA ) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET Company Participants Juliet Cunningham – Vice President-Investor Relations Chris Barry – Chief Executive Officer Matt Harbaugh – Chief Financial Officer Conference Call Participants Matt Miksic – Barclays Shagun Singh – RBC Capital Markets Matt Taylor – Jefferies Vik Chopra – Wells Fargo Juliet Cunningham Thank you. Good afternoon, everyone.
NuVasive (NUVA) came out with quarterly earnings of $0.56 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.47 per share a year ago.
–U.S. Cervical continues to deliver greater than 20% year-over-year growth– –International net sales grew 6.8% as reported and 9.8% on a constant currency basis– SAN DIEGO , Aug. 2, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended June 30, 2023. Second Quarter 2023 Highlights Net sales were $317.8 million, a 2.4% increase as reported and a 3.1% increase on a constant currency basis, compared to the prior year period; GAAP operating margin of 5.7%; Non-GAAP operating margin of 13.3%; and GAAP diluted earnings per share of $0.14; Non-GAAP diluted earnings per share of $0.56.
No recent filings indexed.